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Cost-effectiveness analyses (CEAs) are at the center of health economic
decision making. While these analyses help policy analysts and economists
determine coverage, inform policy, and guide resource allocation, they are
statistically challenging for several reasons. Cost and effectiveness are cor-
related and follow complex joint distributions which are difficult to cap-
ture parametrically. Effectiveness (often measured as increased survival time)
and accumulated cost tends to be right-censored in many real-world appli-
cations. Moreover, CEAs are often conducted using observational data with
non-random treatment assignment. Policy-relevant causal estimation there-
fore requires robust confounding control. Finally, current CEA methods do
not address cost-effectiveness heterogeneity in a principled way - often pre-
senting population-averaged estimates even though significant effect hetero-
geneity may exist. Motivated by these challenges, we develop a nonpara-
metric Bayesian model for joint cost-survival distributions in the presence of
censoring. Our approach utilizes a joint Enriched Dirichlet Process prior on
the covariate effects of cost and survival time, while using a Gamma Pro-
cess prior on the baseline survival time hazard. Causal CEA estimands, with
policy-relevant interpretations, are identified and estimated via a Bayesian
nonparametric g-computation procedure. Finally, we outline how the induced
clustering of the Enriched Dirichlet Process can be used to adaptively de-
tect presence of subgroups with different cost-effectiveness profiles. We out-
line an MCMC procedure for full posterior inference and evaluate frequentist
properties via simulations. We use our model to assess the cost-efficacy of
chemotherapy versus radiation adjuvant therapy for treating endometrial can-
cer in the SEER-Medicare database.
Keywords and phrases: Cost-Effectiveness, Causal Inference, Nonparametric Bayes, Enriched Dirichlet Pro-
cess, Gamma Process, Joint Outcome Modeling, Bayesian Bootstrap
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21. Introduction. Cost-effectiveness analyses (CEAs) are ubiquitous in public health
policy and health economics research, with use-cases ranging from treatment comparison
to determining drug coverage and informing policy. However, they remain statistically chal-
lenging for several reasons. First, cost and effectiveness are often correlated, with joint dis-
tributions typically exhibiting extreme skewness and multimodality. In these settings, para-
metric models that impose strong distributional, linearity, and additivity assumptions are not
tenable. Second, in many cases effectiveness is operationalized as gains in survival time -
which is prone to right-censoring if subjects drop out before the end of the study. For such
patients, we only observe a lower bound on their survival time and accumulated costs. Third,
CEAs are often conducted using observational data which are less expensive and more readily
available, but are prone to confounding. Valid estimation of CEA contrasts therefore requires
adjustment so that differences in cost-effectiveness due to treatment can be disentangled from
differences due to confounders.
Early statistical literature (Lin et al., 1997; Lin, 2000, 2003; Bang and Tsiatis, 2000) fo-
cused on cost estimation, while assuming efficacy was constant between treatments. Cost
estimation alone is challenging due to the pathological nature of costs (censoring, skewness,
zero-inflation, etc). Our work enhances this literature by developing a joint model for cost
and survival time, rather than solely focusing on cost. Previous work decomposed the joint
distribution into a product of a marginal survival time distribution and a cost distribution con-
ditional on survival time. Huang (2002) refer to this as a “calibration regression” approach.
Handorf et al. (2019) and Huang (2002) approach the modeling from a frequentist point of
view. While the former uses a fully parametric approach, the latter uses a semi-parametric
approach - making only first and second moment assumptions. Baio (2014) took a fully para-
metric Bayesian approach to joint modeling that did not allow for full covariate adjustment
since the data application of interest was from a randomized trial. In contrast, our Bayesian
joint modeling approach makes neither strong distributional assumptions nor functional form
(e.g., linearity, additivity) assumptions and allows for covariate adjustment.
Li et al. (2018) took a significant step toward robust causal inference in cost-effectiveness.
They formulate causal CEA contrasts in terms of potential outcomes and develop a doubly-
robust estimation approach that combines separate conditional mean models for cost and
survival with a treatment propensity score model. They show that CEA contrasts can be es-
timated consistently if either the propensity score or cost/survival regressions are correct.
We build on this work in several ways. We also formulate CEA contrasts in terms of po-
tential outcomes - endowing these contrasts with explicitly causal interpretations. However,
our modeling approach is fully nonparametric and, therefore, more flexible than the doubly-
robust estimator. While, the doubly-robust approach only uses data on uncensored subjects
(weighted by the inverse probability of being uncensored) our approach uses data from both
censored and uncensored subjects potentially generating efficiency gains. Moreover, our ap-
proach is a Bayesian model for the full joint cost-effectiveness distribution - not a weighted
combination of separate conditional mean models. This in principle allows for full posterior
inference for any function of the joint distribution. Finally, our approach allows for covariate-
dependent censoring. Though Li et al. (2018) mention an extension to covariate-dependent
censoring, the method proposed and analyzed in their paper relies on randomly censored
survival times.
Specifically, our proposed method decomposes the full joint cost-effectiveness distribution
into a survival distribution, and a cost model conditional on time. We specify a “local" para-
metric cost model and a proportional hazard survival model. A Gamma process (GP) prior
is placed on the baseline hazard of the survival time distribution while an enriched Dirichlet
process (EDP) prior is placed on the cost and survival covariate effects of the local models,
jointly. A key property of the EDP is its induced posterior clustering. The EDP probabilisti-
cally partitions the dataset into clusters with similar cost-effectiveness covariate effects and
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associates different “local" models with each cluster. Thus, the joint posterior model for cost-
effectiveness is an adaptive mixture of locally parametric models. It is adaptive in the sense
that the number of clusters need not be pre-specified. More or less clusters are introduced
depending on the complexity of the cost-effectiveness distribution.
Our work also advances the literature in Bayesian nonparametric (BNP) causal inference.
An array of nonparametric priors have been successfully applied to causal inference problems
(Xu et al., 2016; Xu, Daniels and Winterstein, 2018; Hill, 2011; Kim et al., 2017; Roy, Lum
and Daniels, 2017). For instance, Roy et al. (2018) use an EDP prior to model joint outcome-
covariate distributions and apply the model to causal estimation with missing-at-random co-
variates. However, modeling of bivariate counterfactual outcomes using the EDP and GP has
not been explored. In CEAs, heterogeneity in cost-efficacy is typically either ignored in favor
of a single, marginal effect estimate or is explored along pre-defined subgroups (e.g. hispanic
males). Methods in the heterogenous treatment effects literature such as Bayesian Additive
Regression Trees (BART)-based procedures (Hahn, Murray and Carvalho, 2017; Henderson
et al., 2017) and Causal Forests (Athey and Wager, 2019) are distinct from our approach as
they focus on estimating individual-level treatment effects. Moreover, these methods cannot
be readily applied to the joint outcome setting with censoring. Instead, we use the induced
clustering of the EDP to propose subgroups in a probabilistically principled way. We can then
describe each subgroup of the joint in terms of its covariate, cost, and efficacy distributions
and use these to motivate future, targeted studies. We propose a “Differential Subgroup In-
dex” which measures how much of the cost-efficacy heterogeneity is explained by the EDP’s
partitioning of the joint distribution. This helps us assess the meaningfulness of the clusters.
We begin by providing a brief overview of cost-effectiveness and the desirability of causal
estimands. We then present our model along with a Markov Chain Monte Carlo (MCMC)
algorithm for posterior inference. We incorporate our model into a g-computation framework
for posterior causal effect estimation under specified identification assumptions. Finally, we
outline how the induced clustering of the EDP can be used to explore heterogeneity. Simula-
tion studies assessing frequentist properties of our causal effect estimates under various cen-
soring scenarios and generating models are conducted. We end with a cost-effectiveness anal-
ysis of chemotherapy and radiation therapy treatments for endometrial cancer using SEER-
Medicare claims data.
2. Overview of Relevant Cost-Effectiveness Contrasts. In this paper, we consider a
binary treatment setting where assignment is indicated by A ∈ {0,1}. The goal of CEAs is
to characterize the relative cost-effectiveness of these two treatments - necessitating both a
cost and efficacy measure. In many settings, the total cost, Y , includes all costs accumu-
lated under this treatment - e.g., hospitalization and medication costs incurred due to adverse
events. Moreover, costs are typically measured from the payer’s perspective, not the patient’s
perspective. In single-payer systems like that of the United Kingdom, this would be the Na-
tional Health Service (NHS). For older patients in the United States, as in our data analysis to
follow, the payer of interest is typically Medicare. Though lifetime costs is often of interest,
many CEAs set a duration for cost accrual (e.g. 2-year costs) due to follow-up constraints.
In this paper, we consider a survival time effectiveness measure, D. This is the dominant
effectiveness measure in cancer CEAs, the motivating data application of our paper.
A typical observational CEA study follows diagnosed patients after assignment to one
of two treatment regimes. After some follow-up period, everyone’s (possibly censored) cost
and survival time, are recorded and various cost-effectiveness contrasts can then be com-
puted. For instance, the incremental cost effectiveness ratio (ICER) is given as ICER =
E[Y |A=1]−E[Y |A=0]
E[D|A=1]−E[D|A=0] . This measures the average cost per unit of effectiveness (increase in sur-
vival time). We can also define a monetary value under each treatment, MV (κ) =Dκ− Y .
4Here, κ is the “willingness-to-pay” parameter. It is interpreted as the maximum dollar value
the payer is willing to give for a one unit increase in effectiveness. It is considered a fixed,
user-specified value. Here, we will suppress notational dependence on κ by simply writ-
ing MV where there is no ambiguity. A treatment with positive MV suggests that ac-
crued gains in life value, κD, are greater than accrued costs. Health economists often as-
sess cost-effectiveness via the average net monetary benefit, E[NMB] = E[MV | A =
1]−E[MV |A= 0], where we have again suppressed dependence of NMB on κ. This con-
trast is closely related to ICER and can be interpreted as the average difference in monetary
value between treatment groups. Note that average NMB can also be written equivalently
as E[NMB] = (E[D | A= 1]−E[D | A= 0])κ− (E[Y | A= 1]−E[Y | A= 0]). This is
linear function of κ with the efficacy differential as the slope and the cost differential as the
intercept. Another related quantity is the Cost Effectiveness Acceptability Curve (CEAC),
which is a curve comprised of P (NMB > 0) plotted for various κ.
However, note that MV and NMB presented above have no causal meaning as treated
and untreated subjects may differ systematically in observational studies. This is undesir-
able because many policy questions are inherently causal with the goal being to estimate
the average cost-effectiveness that would have accrued had everyone taken a particular treat-
ment, possibly counter to fact. Estimation of MV with causal meaning requires (1) an esti-
mate of the joint distribution of cost and survival time while adjusting for confounders and
(2) causal identification assumptions. Even if all relevant confounders are measured and in-
cluded in the model, misspecification of the adjustment model may yield biased estimates
of cost-effectiveness contrasts - motivating the need for robust, nonparametric modeling of
the joint. In the following sections we first describe a Bayesian nonparametric model for the
joint outcome conditional on confounders and treatment. We then define a causal NMB as
the difference in average potential monetary value that would have accrued under each treat-
ment. We go on to formulate the identification assumptions required to estimate these causal
quantities using our nonparametric joint model.
3. Joint Nonparametric Model for Cost and Survival Time. We consider a binary
treatment setting in which n patients are assigned to treatment Ai ∈ {0,1} at baseline. Sup-
pose we are interested in contrasting cost-effectiveness over τ periods (e.g. τ = 2 year cost-
effectiveness). We observe dataD = {Yi, Ti,Xi, δi}i=1:n from this study. Here,Xi = (Ai,Li)
is a covariate vector that contains the treatment indicator and a vector of q categorical or con-
tinuous pre-treatment confounders, Li. For notational convenience, we proceed without an
intercept, but note that a 1 can be included in the first entry ofXi. We let Ti =min(Di,Ci, τ)
be the observed time under study (the minimum of a random right-censoring time Ci, end
of study τ , and death time Di). Define a censoring indicator as δi = I(Di > min(Ci, τ))
Finally, Yi ∈ Y denotes cost accumulated through time Ti. The joint distribution can be fac-
tored into a distribution for observed time and cost distribution conditional on time. A joint
model follows from specifying “local" models for each of these two distributions:
Yi | Ti, δi,Xi, ωi ∼ p(Yi | Ti, δi,Xi, ωi)
Ti | δi,Xi, θi, λ0 ∼ λ0(t) exp(X ′iθi)
ωi, θi |G∼ G.
(1)
At a particular time, T , cost follows some local distribution p(Yi | Ti, δi,Xi, ωi) governed
by parameters ωi. Survival time follows some local hazard function which is parameter-
ized as having some baseline hazard, λ0 with covariate effects, θi, multiplying this baseline
hazard. Lastly, ωi and θi - the covariate effects of the cost and effectiveness model - both
follow some joint prior distribution G, which is unknown. Choice of the local models are
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application-specific but are not crucial for model fit, as will become apparent when we dis-
cuss the nonparametric priors used for G and λ0.
One consideration when choosing the local model is desired predictive support. For in-
stance, if costs are sufficiently far from zero, we may be willing to set p(Yi | Ti, δi,Xi, ωi)
to a Gaussian over Y = R with mean and variance ωi = (µi, φi). The corresponding regres-
sion could be specified as µi = (Ti, δi,Xi)′βi. If the non-negative nature of costs must be
respected, we could instead specify a log-normal distribution over Y =R+. For applications
with zero-inflated costs, we may wish to explicitly put positive measure on zero - i.e. set-
ting Y = {0} ∪ R+. This can be done by specifying a two-part model Yi | Ti, δi,Xi, ωi ∼
piiδ0(Yi) + (1− pii)f(Yi | Ti, δi,Xi, βi), where pii = P (Yi = 0 | Ti, δi,Xi, γi) is a covariate-
dependent model for the probability of cost being zero (e.g. a local logistic regression) and
δ0 is the point mass distribution at 0. In this case, the cost parameter vector is ωi = (γi, βi).
Oganisian, Mitra and Roy (2020) developed a nonparametric Bayesian estimation procedure
for such a two-part model, where f could be either log-Normal or Normal, using a Dirichlet
Process prior.
In (1), censored patients contribute to the likelihood through both the cost and survival time
models. In the survival model, they contribute to the likelihood through the survival function
in the usual way, provided that, conditional on covariates, censoring times are independent of
survival times. In the cost model, dead patients provide information about the cost distribution
at death time p(Yi | T =Di, δ = 0,Xi, ωi), while censored subjects inform the model at time
of censoring p(Yi | T =Ci, δ = 1,Xi, ωi).
3.1. Nonparametric Priors. We specify the following nonparametric priors on the un-
known model quantities, G and λ0.
G | αω, αθ ∼ EDP (αω, αθ,G0)
λ0 | b,λ∗0, ξ ∼GP (bλ∗0, b, ξ),
(2)
Above, EDP denotes the Enriched Dirichlet Process (Wade et al., 2014) prior onG and GP
denotes the dependent Gamma Process prior (Nieto-Barajas and Walker, 2002) on the base-
line hazard λ0. These priors are nonparametric in the sense that they are probability measures
on infinite-dimensional objects - the former over probability distributions and the latter over
hazard functions. Realizations, G, from the EDP are discrete probability distributions cen-
tered around a base distribution G0(ωi, θi) = G0ω(ωi)G0θ|ω(θi|ωi) with two concentration
parameters, αω and αθ . Some prior realizations are visualized in Figure 1a. Just as with the
Dirichlet Process (DP), this discreteness induces a posterior clustering of patients. Unlike the
DP, the clustering induced by the EDP is nested. A posteriori, patients with similar cost pa-
rameters are clustered together into what we call ω-clusters. Within each ω-cluster, patients
with similar effectiveness parameters are clustered together (θ-clusters). The EDP prior does
not require pre-specification of the number of clusters. The clustering is data-adaptive, with
more clusters being introduced to capture more complex cost-effectiveness distribution. The
posterior model for the joint distribution is an adaptive nested mixture of cost-effectiveness
models - with each component model having the form of the local model in (1), but with
different component-specific parameters. In the machine learning literature, these models are
often referred to as “mixture of experts” learners: the data space are partitioned into homoge-
nous regions, each having its own model that develops “expertise” in that region. This is in
contrast to ensemble learners (e.g. BART and Random Forests), which apply multiple models
to the entire data and combine the results post-hoc.
The GP can be thought of as a prior over the space of hazard functions. Each realization
λ0 from the GP is a hazard function centered around a mean function λ∗0 with concentration
parameter b. Some prior realizations are visualized in Figure 1b. The process is “dependent”
6(a) (b)
Fig 1: Realizations of the Enriched Dirichlet and Gamma Processes. (a) 100 draws of (θ,ω)∼
G where G ∼ EDP (10,10,N2(0, I2)). Note the nested discreteness of G causes ties (i.e.
clustering) among the draws: there are 80 other draws with the same ω value as the blue
point, but with different θ values. Twenty three of those 80 also have the same θ value. (b)
Gray lines show 50 hazard realizations from a gamma process centered around the hazard of
a Weibull(1.5,2) distribution. The blue line shows the mean of the 50 realizations.
in that it induces a prior AR(1) autocorrelation structure on λ0: the hazard at time point t
is a weighted average of the hazard at the previous time point and the prior hazard, λ0. The
resulting shrinkage/smoothness, controlled by hyperparameter ξ, regularizes the empirical
estimate of the baseline hazard - which can be erratic at later time points when the at-risk set
becomes small.
These prior choices are motivated by the shortcomings of the standard DP. A potential
issue with specifying G∼DP (αG0) is that it imposes a single layer of clustering for both
cost and effectiveness. Many clusters may be introduced to fit the joint of Y and T if one of
these dimensions is more complex - even if the other is very simple. This makes estimates
needlessly variable. The nested nature of the EDP avoids this by allowing varying number
of clusters on each dimension controlled by separate concentration parameters. Thus, it is
possible to introduce a single cost cluster that has many survival time subclusters. Simi-
larly, modeling the baseline hazard separately avoids introduction of excess clusters to fit a
potentially complicated function which, for causal estimation purposes, is just a nuisance pa-
rameter. This is also the reason why we opt for a proportional hazard (PH) formulation rather
than an accelerated failure time (AFT) approach: PH models clearly separate the covariate
effects from the baseline risk, which we do not want influencing the EDP mixture.
3.2. Posterior Inference using Markov Chain Monte Carlo. Inference for (1) is done via
MCMC. We follow the general scheme of Neal’s algorithm 8 (Neal, 2000), which introduces
auxiliary parameters to sample from the DP posteriors. Roy et al. (2018) used this approach
to sample EDP posteriors, though without a Gamma Process update and no joint outcome
considerations. The idea is to introduce latent cluster indicators (the auxiliary parameters)
for each subject. Conditional on draws in the previous iteration, each MCMC iteration then
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updates clustering indicators conditional on parameters and before updating cluster-specific
parameters conditional on these newly updated indicators. At iteration m, we may have J (m)
occupied ω-clusters indexed by j ∈ {1, . . . , J (m)} and, within the jth ω-cluster, we may
have K(m)j occupied θ-clusters indexed by kj ∈ {1, . . . ,K(m)j }. Let c1:n = (c1, . . . , cn) be
cluster assignment indicators where each ci is a length two vector with first and second entry
indicating membership to an ω-cluster and θ-subcluster, respectively. Throughout, we use the
notation va:b, where a < b are integers, to denote the collection (va, va+1, . . . , vb) . Let ω[j]
represent the cost parameter associated with cluster j and θ[j,k] represent the effectiveness
parameter associated with the kth subcluster of ω-cluster j. We should strictly denote θ[j,k]
as θ[j,kj ] but suppress the subscript throughout wherever reference is clearly made to the k
th
subcluster of ω-cluster j. Moreover, define n−ij and n
−i
j,k as the number of subjects (excluding
subject i) currently occupying ω-cluster j and ω-θ cluster (j, k), respectively, at the current
iteration, m. At each iteration m we conduct the following sequence of conditional posterior
updates:
• Update cluster membership:
– Propose parameters for a new θ-subcluster for each existing ω-cluster, {θ[j,K(m)j +1] : j ∈
1, . . . , J (m)} by drawing from the prior G0.
– Similarly, propose parameters for a new ω-cluster with a θ subcluster, {ω[J(m)+1], θ[J(m)+1,1]}.
– Conditional on current draws of all cost-effectiveness parameters and λ(m)0 (indicated
by “−” for compactness), update c(m)i according to the following probabilities:
P (c
(m+1)
i = (j, k) | −,D)∝

n−ij n
−i
j,k
n−ij +αθ
p(Yi, Ti |Xi, δi, ω(m)[j] , θ(m)[j,k], λ(m)0 ) for existing j, k
n−ij αθ
n−ij +αθ
p(Yi, Ti |Xi, δi, ω(m)[j] , θ(m)[j,K(m)j +1], λ
(m)
0 ) for existing j, new k
αωp(Yi, Ti |Xi, δi, ω(m)[J(m)+1], θ
(m)
[J(m)+1,K
(m)
j +1]
, λ
(m)
0 ) new j, k
• Update cluster parameters: These require Metropolis-Hastings steps if G0ω or G0θ|ω are
not conjugate.
– Update each cluster’s cost parameter, ω[j], by drawing from conditional posterior
ω
(m+1)
[j] ∼ p(ω[j]|c
(m+1)
1:n ,D)∝G0ω(ω[j])
∏
i|c(m+1)i ∈(j,·)
p(Yi|Ti,Xi, δi, ω[j])
– For each j, update all θ[j,kj ] by drawing from conditional posterior
θ
(m+1)
[j,k] ∼ p(θ[j,k]|c
(m)
1:n , λ
(m)
0 ,D)∝G0θ|ω(θ[j,k])
∏
i|c(m)i ∈(j,k)
p(Ti |Xi, δi, λ(m)0 , θ[j,k])
• Update baseline hazard, λ(m+1)0 : This is a multi-step update involving a discretization of
the time interval [0, τ ] into increments, then modeling the hazard rate in each increment.
This is motivated by the fact that if λ0 follows a Gamma Process, then the hazard rates
in any finite partition of the time interval have Gamma distributions (Nieto-Barajas and
Walker, 2002). Additionally, the latent parameters inducing the AR(1) smoothness across
increments are also updated with a mix of grid sampling and adaptive Metropolis steps.
Details are provided in Appendix B.
Note that the induced nested clustering of the EDP is explicitly encoded into this sampler.
In the cluster-update step, a given subject is most likely to be assigned to the cluster with
parameters that yield the highest joint-distribution evaluation (i.e. fit their data the best).
Moreover, each subject can possibly be assigned to a new cost cluster, new effectiveness
8cluster within an existing cost cluster, or a new cost-effectiveness cluster. This last event is
likely to occur if, for example, the subject is so unique that random parameter draws from
the prior fit that subject’s data better than any of the existing cluster-specific parameters.
Furthermore, note that each term for an existing cluster in P (c(m+1)i = (j, k) | −,D) is an
increasing function of the number of patients already assigned to that cluster. This is the “rich-
get-richer” property of the EDP - the a priori favoring of assignment to larger clusters. This
prevents over-fitting by penalizing small clusters. After every cycle, c(m+1)i maps each subject
to a set of updated parameters (ω(m+1)i , θ
(m+1)
i , λ
(m+1)
0 ). After a sufficient burn-in period this
algorithm produces M draws from the posterior {ω(m)1:n , θ(m)1:n , λ(m)0 , c(m)1:n }1:M . These can be
used to do full posterior inference on any functional of the joint including, as we will see,
causal estimands.
3.3. Priors and Hyperparameter Choice. The hyperparameters for the EDP are the base
distribution G0(ωi, θi) =G0ω(ωi)G0θ|ω(θi|ωi) and the concentration parameters αθ and αω .
Following previous papers (Oganisian, Mitra and Roy, 2020; Roy et al., 2018), we use prior
independence so that G0(ωi, θi) = G0ω(ωi)G0θ(θi) and set G0θ(θi) = N(θˆPH , νθCˆPH).
Here, we are centering the cluster-specific covariate effects around the Cox proportional haz-
ard estimate, θˆPH . The prior covariance matrix, CˆPH , is diagonal with the square of the Cox
proportional hazard standard error estimates along the diagonal. The parameter νθ > 0 is a
user-specified scalar that controls how tightly or widely dispersed the cluster-specific effects
are around the Cox estimates.
The choice of G0ω(ωi) depends on the choice of local cost model. Suppose our local
model, p(YiTi, δi,Xi, ωi) is Gaussian, N(µi, φi) with regression µi =E[Yi | Ti, δi,Xi, ωi] =
(δi, Ti,Xi)
′βi and variance φi, where βi is the vector of covariate effects. The full cost param-
eter vector is ωi = (βi, φi) and we could set G0ω(βi, φi) = N(βi; βˆ, νωΣˆ)IG(φi;shape =
a0, scale = sˆ
2(a0 − 1). The vector βˆ is the MLE estimate of the cost regression and Σˆ
is a diagonal matrix with the square of the standard error estimates along the diagonal.
The parameter νω > 0 is user-specified and controls the tightness of the prior around βˆ.
Similarly, the Inverse Gamma prior for φi having mean equal to the empirical outcome
variance, sˆ2 = 1n−1(Yi − Y¯ )2. The user-specified parameter, a0, controls how widely the
cluster-specific variances are dispersed around the empirical variance, with higher values
corresponding to a tight prior around the empirical estimate. Finally, we follow previous
approaches (Roy et al., 2018; Oganisian, Mitra and Roy, 2020) and set Gam(1,1) (i.e. flat,
uninformative) priors on each of the concentration parameters. These parameters can be inter-
preted as prior sample sizes for the cost and effectiveness clusters - higher values on average
lead to more occupied clustering. Thus, this Gamma prior penalizes many occupied clusters,
but has a long tail to allow posterior deviations if demanded by the data.
Finally, we center the Gamma Process prior around a constant hazard function. Specifi-
cally, we compute the Nelson-Aalen estimate of the baseline cumulative hazard, then take
the difference between each point on this curve to obtain the baseline hazard estimate at
each time point. We then compute the average of these hazard rates across time, λˆ. Then,
in GP (bλ∗0, b, ξ) we can set λ∗0 to be exponential with rate λˆ. Intuitively, this expresses the
prior belief of a constant hazard (with rate in the range of the observed rates). However, if
the data disagrees, the posterior will move us to a richer estimate governed by the data. The
parameters ξ and b can be used to calibrate degrees of informativeness. For example ξ near
zero and large b corresponds to an informative prior belief of a constant hazard. Conversely,
values of b near 0 correspond to an uninformative prior.
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4. Posterior Causal Estimation via g-Computation. Here we describe full posterior
inference for various causal estimands expressed in terms of potential outcomes (Rubin,
1978). In scenarios with censored outcomes, causal estimands are typically formulated un-
der a hypothetical “joint intervention” (Robins, Hernán and Brumback, 2000) on both treat-
ment and censoring. Let MV A=a,δ=0 =DA=a,δ=0κ− Y A=a,δ=0 be the monetary value that
would have accrued over τ periods had the patient received treatment a and not been cen-
sored. The components Da,0 and Y a,0 are the survival time and costs, respectively, that
would have been observed under treatment A = a had the subject not been censored. The
population-level estimand of interest is Ψ = E[NMB] = E[MV 1,0] − E[MV 0,0]. This is
the average difference in monetary value that would have accrued over τ periods had every-
one in the target population been assigned to treatment 1 versus treatment 0, and not been
censored. In general, interventions in observational CEAs are not random. Instead, they are
driven by confounders - factors which both influence treatment and cost-effectiveness. Thus,
E[MV a,0] 6= E[MV |A= a, δ = 0] in general, since those who actually received treatment
and remained uncensored may not be representative of the target population. Suppose, how-
ever, that we observe a set of pre-treatment confounders, L. Under the following extensions
of the usual causal identification assumptions, we can identify Ψ:
IA.1 Joint ignorability: (Y a,δ,Da,δ)⊥ (A,δ) | L. Conditional on L, censoring and treatment
should be as good as random - being completely independent of the death and costs that
would have accrued under a particular treatment. Omission of unmeasured drivers of both
the joint intervention or cost-effectiveness would result in a violation of this assumption.
IA.2 Joint Consistency: (Y a,0,Da,0) = (Y,D) | A = a, δ = 0. This requires that cost and
death time observed for an uncensored (δ = 0) subject assigned treatmentA= a is actually
(Y a,0,Da,0). This could be be violated if, for instance, we had non-compliance to the
treatment. Then, a subject assigned a may not have actually taken a and thus we would not
observe Y a,0.
IA.3 Joint Positivity: 0 < P (A = a, δ = 0 | L) < 1. The joint intervention cannot be deter-
ministic at any level of L. This could be violated if, for example, all uncensored males
received treatment A= 1 - leaving us with no information on how well uncensored males
with treatment A= 0 faired. In these cases, the model may extrapolate the outcome under
treatment A= 0 learned from females onto males. Poor extrapolation could lead to bias.
IA.4 No Joint Interference: (Y a1:n,δ1:ni ,D
a1:n,δ1:n
i ) = (Y
ai,δi
i ,D
ai,δi
i ). Here, a1:n and δ1:n are
n−dimensional vectors containing each subject’s treatment and censoring status. This as-
sumption requires that one person’s joint treatment-censoring intervention cannot impact
another’s cost-effectiveness. It allows us to drop all but the ith element of a1:n and δ1:n.
Usually this assumption would be violated in infectious disease exposures or other settings
where subjects cannot be reasonably viewed as exchangeable (one person’s infection status
may impact another’s infection probability).
Under these assumptions, Ψ is identified via Robins’ g-formula (Robins, 1986)
Ψ(ω1:n, θ1:n, λ0) =
∫
L
(
E[MV |A= 1, δ = 0,L,ω1:n, θ1:n, λ0]
−E[MV |A= 0, δ = 0,L,ω1:n, θ1:n, λ0]
)
dP (L)
(3)
Details are provided in the Appendix A. Above, we have explicitly written Ψ = Ψ(ω1:n, θ1:n, λ0)
as a function of the parameters governing the joint cost-effectiveness distribution. This is to
highlight that a posterior distribution over these parameters induces a posterior on the the
causal estimand Ψ. Let each expectation in (3) be denoted as µ(a,0) = E[MV |A= a, δ =
0,L,ω1:n, θ1:n, λ0]. Then,
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(4) µ(a,0) =
∫ τ
0
∫ ∞
0
(Dκ− Y )p(Y,T | L,A= a, δ = 0, ω1:n, θ1:n, λ0)dY dD
Where this inner integration is over the joint model we presented in (1) with Xi = (Ai,Li).
Note that conditional on δ = 0, T = D in the joint model and we integrate along the time
up until τ - resulting in τ -period monetary value. This integration can be done efficiently via
Monte Carlo (see Appendix B).
The outer integration over L in (3) requires an estimate of P (L). To avoid strong para-
metric assumptions, we use a Bayesian bootstrap (Rubin, 1981). That is, we express p(L) as
a discrete distribution with mass pi at the ith observed confounder vector Li. Specifically,
p(L= l) =
∑n
i=1 pi · δLi(l). Here δLi is a point-mass at Li. The Bayesian bootstrap follows
from an improper Dirichlet prior on the weights, p1:n = (p1, . . . , pn) ∼Dir(0, . . . ,0). This
yields a conjugate posterior p1:n | L ∼ Dir(1, . . . ,1) with n−dimensional posterior mean
vector E[p1:n | L] = (1/n,1/n, . . . ,1/n).
At the end of the mth iteration of updates from Section 3.2, we have a set of parameter
draws {ω(m)1:n , θ(m)1:n , λ(m)0 }, which we can use to construct a posterior draw of monetary value
µ
(m)
i (a,0) = E[MV | A = a, δ = 0,Li, ω(m)i , θ(m)i , λ(m)0 ]. We then take a draw p(m)1:n from
the Dirichlet posterior and construct a draw of the confounder distribution p(m)(L = l) =∑n
i=1 p
(m)
i · δLi(l). Substituting both of these into (3), yields a draw from the posterior of Ψ
(5) Ψ(m) ≈
n∑
i=1
p
(m)
i
(
µ
(m)
i (1,0)− µ(m)i (0,0)
)
Repeating for iterations m = 1, . . . ,M yields M draws from the posterior of the causal
τ -period NMB: {Ψ(m)}1:M . The mean of these draws can serve as a Bayesian nonparametric
point estimate of Ψ and percentiles of the M draws can be used to form credible intervals.
The posterior draws can also be used to compute a point on the CEAC for each κ,
P (NMB > 0 | D) ≈ 1M
∑
m I(Ψ
(m) > 0). We note that, from this Bayesian perspective,
each point on the CEAC is a posterior p-value or tail-area probability. If individual-specific
estimates are required, Equation (4) can be evaluated for particular Li under both treatments
using each of the m posterior parameter draws. The difference would be a draw from the
posterior of Ψi = NMBi(κ), denoted Ψ
(m)
i = µ
(m)
i (1,0) − µ(m)i (0,0). In the causal liter-
ature, these are variously referred to as conditional average treatment effects (CATEs) or
individual treatment effects (ITEs). Across M iterations, we would also have subject-level
credible intervals for Ψi. Figure 2a visualizes posterior mean and intervals for each Ψi using
an illustrative synthetic example.
5. Adaptive Subgroup Discovery. The MCMC scheme of Section 3.2 yields poste-
rior draws of latent cost-effectiveness cluster membership, {c(m)i }1:M . In this section, we
propose using these draws to adaptively discover subgroups of patients with different cost-
effectiveness profiles. This is “adaptive” in the sense that the number of clusters is not pre-
specified, but grows or shrinks as the model adapts to the data complexity. Subgroup discov-
ery is a policy-relevant endeavor since current CEA practice tends to focuses on marginal,
population-level analyses - even if there is significant variation in the target population. Exist-
ing approaches to heterogeneity Hahn, Murray and Carvalho (2017); Henderson et al. (2017);
Athey and Wager (2019) focus on computing ITEs and use post-hoc heuristic procedures to
characterize this heterogeneity across pre-defined subgroups - rather than proposing sub-
groups adaptively.
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Fig 2: Clustering results from EDP-GP fit using synthetic data with two latent cost-
effectiveness clusters. Here, EDP-induced clusters on the joint distribution capture differ-
ences in NMB. Panel 2a shows posterior point and 95% interval estimates Ψi (with κ= 1).
Colors indicate posterior model cluster assignment, c∗1:n. Panel 2b visualizes the posterior
probability matrix P . Panel 2c is the posterior distribution of DSI - indicating that about
70% of the variation in subject-level Ψi is explained by the EDP clustering. However, this
need not be the case. The EDP clusters may be capturing complexities unrelated to NMB.
While this is desirable to obtain a good fit to a complex distribution, it means the clusters
have no substantive meaning. The DSI is necessary to distinguish between these scenarios.
Using the given MCMC outputs for subgroup discovery is challenging for two reasons.
First, the vector of cluster assignment labels, c(m)1:n , have no meaning across MCMC itera-
tions - making it difficult to determine the posterior mode partition. This is known as label
switching (Stephens, 2000). To illustrate, consider that a new cost-effectiveness cluster forms
in iteration m+ 1 and all subjects previously in another cluster are re-assigned to this new
cluster. In this case, even though the assignment has changed, the underlying composition of
the cluster did not. As a solution, we propose to keep track of the n× n adjacency matrix
C(m), where the ijth element, C(m)ij , is a binary indicator of subject i and j being in the same
cost-effectiveness cluster at iteration m. Note that this is just the vector c(m)1:n re-arranged into
a matrix. Taking the elementwise mean of this matrix across the m posterior draws yields a
probability matrix P = (1/M)∑m C(m) where ijth element, Pij , is the posterior probability
of subject i and j being in the same cost-effectiveness cluster. To get a hard clustering assign-
ment, we then search draws, {c(m)1:n }1:M , for the assignment that is “closest” to P . That is, we
search for c∗1:n = arg minm ||C(m)−P||, where || · || is some matrix norm. As in earlier papers
on Bayesian clustering, here we adopt “Binder’s Loss” || · || =∑i,j(C(m)ij − Pik)2 (Binder,
1978; Dahl, 2006). This essentially approximates the posterior mode of the EDP-induced
partition, P . Figure 2b visualizes P from an illustrative synthetic example as a weighted
graph where each subject is a node and the length of vertices connecting two nodes are in-
versely proportional to Pij . Subjects with low posterior probability of being in the same
cost-effectiveness cluster are far apart on the graph. Such figures are good tools for assessing
uncertainty in posterior mode assignments, c∗i . For instance, the points between the group of
dark red and blue clusters represent subjects with highly uncertain mode assignments. The
covariate effects of these subjects look just as similar to the well-separated dark blue points
as they do to the well-separated dark red points.
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A second challenge with using the assignments for subgroup discovery is that the EDP
clusters are not explicitly designed to cluster on NMB. The clustering is driven by the com-
plexity of the joint cost-effectiveness distribution. This is necessary for a flexible joint distri-
bution estimate, but may not translate into meaningful NMB clusters. For instance, consider
a bimodal cost-effectiveness distribution with two groups having very different mean costs.
However, the difference in costs between treatment groups in both clusters may be the same.
In this case, the EDP will likely introduce two clusters with similar NMBs. This begs the
question: are the clustering results detecting subgroups with different cost-effectiveness pro-
files? To answer this question, we propose a posterior Differential Subgroup Index (DSI)
that, at each MCMC iteration, computes the proportion of the total variation in the ITEs,
Ψ
(m)
i , that is explained by the cluster partition in that iteration. First, define the mean NMB
in subject i’s cluster at iterationm: Ψ¯(m)i =
1∑
j I(c
(m)
j =c
(m)
i )
∑
j|c(m)j =c(m)i Ψ
(m)
j . Then theDSI
measure is,
(6) DSI(m) =
∑
i
(
Ψ¯
(m)
i −Ψ(m)
)2
∑
i(Ψ
(m)
i −Ψ(m))2
This intuitively plays the same role as a regression R2 statistic. Across the m iterations, we
have a set of draws for this statistic, {DSI(m)}1:M , which reflects our uncertainty about
how well the clustering is capturing heterogeneity in NMB. A posterior distribution for
DSI concentrated near 1 suggests that the EDP-induced clustering explains nearly all of
the variation in the subject-specific NMBs. This implies that the EDP-induced clustering at
the joint cost-effectiveness level is capturing variation at the NMB level. Figure 2c plots the
posterior distribution for DSI for an illustrative synthetic example generated with two cost-
effectiveness clusters. We can then summarize our data along the mode partition, c∗1:n. For
instance, in the synthetic example, we can create a table summarizing the observed costs, sur-
vival, and covariate distributions of the two identified clusters. These can be used to motivate
future cost-effectiveness studies targeting these subgroups. The DSI also provides context
for our marginal posterior estimate, Ψ. A high DSI indicates that a marginal estimate is not
capturing substantial treatment effect heterogeneity detected by the EDP posterior.
6. Assessing Frequentist Properties via Simulation. In this section we report results
of several simulation experiments exploring the frequentist properties (i.e. bias, coverage, and
precision) of our posterior mean and interval estimates for Ψ under a variety of settings. These
results are reported in Table 1. We simulate data with one continuous confounder, four binary
confounders, and a binary treatment. We simulate survival times conditional on treatment
and confounders from a Weibull distribution. Survival times are censored by censoring times
that also follow a covariate-dependent Weibull distribution. We simulate an outcome from
a true Y distribution of either a Gaussian or Log-Normal, with confounder- and treatment-
dependent means. Data were simulated under low (5%) and high (20%) covariate-dependent
censoring. For each of these, we simulate under a parametric and bimodal setting. Under
the parametric setting, the joint distribution is unimodal - leading to a simple joint cost-
survival distribution. Under the bimodal setting, we simulate data from a mixture of two
cost-effectiveness distributions, each having different covariate effects in the cost and survival
time models. In each of these eight settings, we simulate 200 datasets with 1500 subjects
each. Details about the data generation are given in Appendix C.
We include the doubly-robust estimator (DR-SL) of Li et al. (2018) as a comparator.
This approach involves estimating separate models for conditional mean cost and condi-
tional mean survival time via super learner. Predictions from these models are weighted by
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TABLE 1
Simulation Results. Average bias of posterior mean NMB (as discussed in Section 4 ) along with coverage and
average width of 95% credible/confidence interval (CI) is reported for EDP-GP model. Point estimate is
reported for DR-SL along with coverage and width of 95% bootstrap BCa interval. Bias is reported as a
proportion of the truth. Censoring rate was 5% in the low setting and 20% in the high setting. Willingness-to-pay
is set to κ= 1. Results are across 200 simulated datasets with N = 1500 subjects each.
Simulation Setting EDP-GP DR-SL
True Y Dist. Joint Dist. Censoring Bias Coverage Width Bias Coverage Width
Gaussian
Parametric
Low -0.002 0.94 0.11 -0.001 0.95 0.18
High -0.002 0.97 0.12 0.003 0.95 0.30
Bimodal
Low -0.01 0.94 0.13 0.11 0.60 0.64
High -0.01 0.94 0.14 0.16 0.40 0.77
Log-Normal
Parametric
Low -0.02 0.92 0.13 -0.001 0.96 0.12
High 0.004 0.96 0.14 -0.01 0.96 0.13
Bimodal
Low -0.004 0.98 0.11 0.02 0.94 0.18
High 0.03 0.92 0.12 0.06 0.90 0.20
the product of the inverse probability of treatment and inverse probability of censoring. We
estimate the former using a correctly specified logistic regression - which suggests the DR es-
timate will be consistent but may still have substantial bias in finite samples if the models are
inadequate. For the latter, we note that Li et al. did not consider the covariate-dependent cen-
soring in their analysis. Instead, they estimate the probability of censoring in both treatment
groups separately via Kaplan-Meier. Li et al. suggest using a discrete-time failure model in
situations with covariate-dependent censoring. Here, we contribute to the literature by imple-
menting this suggestion using a logistic regression. In the super learner libraries, we include
regression trees, generalized additive, linear models, as well as elastic net generalized lin-
ear model (GLMnet). As recommended by Li et al., we using the bootstrap BCa interval for
inference.
For the EDP-GP, we run using independent Gaussian base distributions forG0 that are null
centered with flat priors, relative to the data variance. Importantly, we use a local conditional
Gaussian model for Y . We set λ∗0 to an exponential (constant) hazard. Additional details
on DR-SL and EDP-GP settings are provided in Appendix C. To summarize, the unimodal
setting with Normally distribution Y is the most favorable setting for our method since the
Gaussian data generating model matches the local Gaussian model we specify. In principle,
all of these settings are quite favorable to the DR-SL method since we correctly specify the
propensity score model. The log-Normal setting is the least favorable to our method since our
local Gaussian model is misspecified. Notice that in all censoring and Y distribution settings,
the parametric data generating process yields low bias and close to nominal coverage for both
methods. This is as expected since both are highly flexible models, they should perform well
in simple settings. Note however, that the models diverge in the more complicated, bimodal
setting. In the bimodal log-Normal setting, the DR-SL exhibits higher bias with a larger inter-
val width relative to EDP-GP. Similarly, in the bimodal Gaussian setting, the DR-SL model
exhibits particularly high bias - 11% and 16% in the low and high settings, respectively. The
main challenge with DR-SL is that the underlying super learner fails to capture biomodality
in the cost-effectiveness joint distribution. In contrast, the EDP partitioning picks up the bi-
modality - modeling each mode with separate parameters to attain a better overall fit. Finally,
note that EDP-GP intervals tend to be narrower across settings.
7. Cost-efficacy of Endometrial Cancer Treatment. We apply our BNP method to as-
sess the cost-effectiveness of adjuvant chemotherapy (CT) versus radiation therapy (RT) for
the treatment of endometrial cancer and compare our results to the DR-SL estimate. The tar-
get population of interest are women over the age of 65 who were diagnosed with endometrial
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cancer before undergoing hysterectomy. Within three months after hysterectomy, patients
are assigned to either adjuvant RT or CT. We select a cohort of women over the age of 65
who were diagnosed with endometrial cancer between 2000 and 2014 in the SEER-Medicare
database. The first treatment after three months of diagnosis was recorded. A maximum of
τ = 24 months of follow-up after hysterectomy was available in this data cut. Total costs ac-
crued by Medicare (including inpatient, outpatient, hospice, and pharmaceutical costs) were
recorded along with their survival/censoring status. Covariates which are known drivers of
treatment assignment (age, comorbidities, cancer stage) were extracted. Table 2 displays sum-
mary statistics for the sample. Notably, the 2-year survival is slightly lower in the CT arm
(93% vs. 94.5%), and average total costs higher in the CT arm (51.3 vs. 42.6). This suggests
worse cost-effectiveness for CT relative to RT. However, there is significant uncertainty asso-
ciated with these numbers that should be quantified. Moreover, the cohorts differ substantially
in terms of observed characteristics at treatment assignment. For instance, the radiation arm
has a greater proportion of patients with baseline International Federation of Gynecology and
Obstetrics (FIGO) stage of IB - which is more severe than IA and I-NOS. Similarly, RT harm
has fewer comorbidities - with 57% (vs. 54%) having Charlson Comorbidity Index of zero.
These differences could differentially affect adjuvant therapy assignment and cost-efficacy.
TABLE 2
Sample Characteristics: Mean and sample standard deviations reported for continuous covariates. Counts and
proportions reported for categorical covariates. Standardized mean differences (SMD) are provided. Typically
SMD> .1 indicate large differences. Monetary amounts are in thousands of 2018 U.S. Dollars.
Radiation Chemotherapy SMD
(N= 3,827 ) (N= 245 )
Total Accrued Costs ($) 42.6 (36.8) 51.3 (39.7) .23
2-yr Survival Prob. 94.5 93.0
Age (years) 73.6 (6.2) 73.2 (6.3) .06
Household Income ($) 60.3 (28.8) 65.6 (34.0) .17
Charlson Index .12
0 2176 (56.9) 131 (53.5)
1 1056 (27.6) 65 (26.5)
2 342 (8.9) 30 (12.2)
≥ 3 253 (6.6) 19 (7.8)
FIGO Stage .5
I-NOS 353 (9.2) 23 (9.4)
IA 1162 (30.4) 128 (52.2)
IB 1780 (46.5) 64 (26.1)
II/II-NOS 532 (13.8) 30 (12.2)
We use our EDP-GP approach to compute posterior point and interval estimates for NMB
while adjusting for differences in observed covariates. We specify the local cost distribution,
p(Yi | Ti, δi,Xi, ωi), to be a log-normal distribution with parameters ωi = (βi, φi). The local
regression is
E[Yi | Ti, δi,Ai,Li, ωi] = exp
{
(1,Li,Ai, Ti, δi)
′βi + φi/2
}
This local log-normal distribution respects the non-negative nature of costs, while allowing us
to capture skewness. In the model, Li includes household income, Charlson index, and FIGO.
FIGO is included as a categorical covariates, while the others are treated as continuous. We
let A= 1 indicate assignment to chemotherapy with radiation being reference.
We set prior G0 as discussed in Section 3.3: G0ω(βi, φi) = N(βˆ, Σˆ)IG(a0, φˆ(a0 − 1)).
Here, βˆ are OLS estimates using log(Y ) as the outcome and Σˆ = diag(1, .012, . . . , .012).
Note the latter appears overly informative, but is actually fairly wide on the exponentiated
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Fig 3: Posterior estimates of (a) NMB for various willingness-to-pay for each additional
month of survival, κ. The posterior distribution of DSI in (b) shows that about 15% of the
variation in the individual-level NMBs is explained by the EDP induced clustering. This
suggests the treatment effect may be relatively homogeneous and the NMB is a good overall
average effect measure. In panel (c) we have plotted the posterior baseline hazard curve
along with 95%, 90%, and 80% credible bands in successively darker shades. Notice that
posterior estimate is smoother version of the empirical estimate hazard in red. It is a posterior
compromise between the empirical hazard and the prior constant hazard.
scale. That is, a prior variance of 1 implies that mean costs as large as exp(1 ·1.96)≈ 7 times
the empirical mean cost are plausible. Similarly, a prior variance of .01 implies covariate
effects of as large as 2% = 1− exp(1.96 ∗ .01) are a priori plausible in the absence of data.
For φ, note that the variance of the log-Normal random variable, Z , is V ar[Z] = (eφ −
1)E[Z]2, which implies φ= log[V ar[Z]/E[Z]2 +1]. This motivates setting φˆ= log[sˆ2/y¯2 +
1], where sˆ2 and y¯ are the marginal variance and mean of the observed cost values. We
set a0 = 1000, which anchors the prior around the empirical estimate. For the effectiveness
model we again follow Section 3.3 and set G0θ(θi) = N(θˆPH , I). We center the GP priors
around an empirical estimate λ∗0(t) = λˆ ≈ .001 with b = 2000 and ξ = 4000. Here, ξ is on
the order of the sample size - signifying strong AR(1) smoothing. The value b is about half
of ξ - putting equal a priori weight on the prior hazard λ∗0(t) and the previous hazard at time
t− 1.
We run three MCMC chains in parallel for 5,000 iterations and discard the first 3,000
draws of each chain as burn-in. We initialize each chain with different numbers of initial cost
and effectiveness clusters and check that the chains converge to each other regardless of this
initialization. This yields a total of 6,000 draws which we use for posterior inference. Other
details and assessments of convergence are provided in Appendix D.
We estimate a 2-year NMB of chemotherapy over radiation to be −$14.5 thousand, with
95% CI [−$16.6,−$12.7]. This assumes a willingness-to-pay of about κ = $4167/month,
or $50,000/year of life gained - which is standard in cost-effectiveness analyses. This is
roughly consistent with the unadjusted comparison in Table 2, where average total costs
among chemotherapy patients was higher by about $9,000. Figure 3a shows average NMB
as a function of κ for various κ values. Recall that by definition NMB is a linear function
of κ. The intercept at κ = 0 shows an NMB that captures differences in cost only (efficacy
has zero value). The negative y-intercept here reflects that even if we do not value efficacy,
chemotherapy is more expensive than radiation after covariate adjustment. The negative slope
of the curve reflects that adjusted efficacy (i.e. survival benefit) of chemotherapy is lower.
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However, the slope here is quite small, suggesting a very small difference in efficacy. This is
consistent with unadjusted results - recall from Table 2 that 2-year survival is slightly lower
among chemotherapy patients.
In terms of clustering, we compute c∗1:n as given in Section 5 and find that about 86%
of the observations are grouped into two posterior mode clusters. However, in Figure 3b
we see that only about 15% of the variation in the individual-level NMBs is explained by
the EDP-induced partition - which suggests these clusters are not very meaningful for cost-
effectiveness. This indicates low posterior evidence of treatment effect heterogeneity, sug-
gesting average NMB may fairly characterize the cost-effectiveness profile. Finally, Figure
3c shows the posterior estimate of the baseline hazard. Since continuous covariates were
normalized, this represents the hazard among patients with average household income and
age with Charlson index of zero and FIGO II/II-NOS. This has no explicit causal interpre-
tation but is illustrative of the Gamma process. Notice our posterior has moved away from
the constant hazard prior and towards the empirical (Nelson-Aalen) estimate shown in red.
The informative AR(1) shrinkage results in a smoother posterior curve that penalizes large
swings in the empirical hazard.
For comparison, we also ran the DR-SL approach where propensity score model, mean
survival time model, and mean cost model were all estimated using super learner. Regression
trees, GLMnet and GLM were included as candidate learners and 95% BCa intervals were
estimated using 5,000 bootstrap iterations. For willingness-to-pay κ = $4167/month, DR-
SL estimates a 2-year average NMB of −$11.8 with 95% CI [−$19.1,−$6.0] in thousands.
This is similar to our estimate of −$14.5 [−$16.6,−$12.7], but the DR interval is wider.
More details on the DR-SL implementation are given in Appendix D, including a full plot of
average NMB from DR-SL as in Figure 3a. For even large willingness-to-pay values of up to
300 thousand USD per year, both approaches find a negative NMB with intervals excluding
zero. This supports the relative cost-effectiveness of radiation over chemotherapy adjuvant
therapy over two years.
8. Discussion. Cost-effectiveness is statistically challenging due to the complexities of
the joint distribution of cost and survival time, such as skewness, censoring, and multi-
modalities. Moreover, estimation of policy-relevant estimands with causal interpretation
is complicated by confounding in observational studies. Robust causal inference for cost-
effectiveness requires flexible modeling that accounts for these complexities while adjusting
for confounders. In this paper, we outlined a nonparametric Bayesian solution that leverages
the Gamma and enriched Dirichlet process priors to model the joint distribution of cost and
survival time. We proposed cost-effectiveness estimands with causal meaning and identified
them under suitable causal assumptions. We showed how our model can be used in a Bayesian
g-computation procedure that draws from the posterior of the causal effect. Finally, we show
that the partition induced by the EDP can be used to explore cost-effectiveness heterogeneity
and introduced the DSI diagnostic statistic for assessing how well this partition captures
heterogeneity.
In simulations, we demonstrated that our procedure has adequate frequentist properties
(bias, coverage, etc.) in a variety of scenarios. In complex settings, it can be comparable and,
at times, outperform existing doubly-robust methods. Across almost all settings, the EDP-
GP produces NMB estimates with narrower interval widths relative to the DR-SL estimates.
In the data analysis, the DR-SL approach also yields wider intervals. One driver of this is
the relative inefficiency of the DR-SL approach. This method only uses data from patients
who are not censored and weights their contributions by the inverse probability of being
uncensored. In contrast, our method uses censored patients, since they still inform the total
cost distribution at their observed time. Another feature with the DR-SL is that it is a weight-
based estimator (weighted both by inverse probability of treatment and censoring), which
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are known to be quite variable if the probability of treatment are near the bounds within
subgroups. Since the EDP-GP approach is model-based, it provides more smoothing under
these conditions. Finally, the bootstrap inference procedure used in the DR-SL approach can
be difficult to implement in practice, where sparsity among categorical covariates leads to
the occasional pathological bootstrap resample (e.g. with rank deficient matrix). This is in
contrast to full posterior inference via the Bayesian bootstrap which can be more stable.
Finally, we see at least two avenues of future work and extensions. First, in our paper,
we consider a setting with a single baseline treatment. This allows us to estimate the cost-
effectiveness of baseline treatments, which are highly relevant in many settings. However,
we may also wish to estimate the cost-effectiveness of time-varying treatment regimes, in
addition to the effect of the initial baseline treatment. Flexible causal estimation in these
settings is more complex and should be explored. Second, there has been much work on
improving the computational scalability of posterior inference on Dirichlet process models,
including both approximate inference via Variational Bayes and parallel MCMC procedures.
Future work developing scalable inferential procedures for joint-modeling with EDPs can be
useful.
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APPENDIX A: IDENTIFICATION OF CAUSAL NET MONETARY BENEFIT
Recall that we are interested in estimating Ψ =E[MV 1,0]−E[MV 0,0], where the expec-
tation implicitly conditional on the parameters governing the joint cost-survival distribution.
We can identify each term of Ψ. Starting with an iterated expectation over L,
E[MV a,0] =EL[EY,D[MV a,0 | L,ω1:n, θ1:n, λ0]]
=EL[EY,D[MV a,0 |,A= a, δ = 0,L,ω1:n, θ1:n, λ0]]
=EL[EY,D[MV |A= a, δ = 0,L,ω1:n, θ1:n, λ0]]
=
∫
L
EY,D[MV |A= a, δ = 0,L,ω1:n, θ1:n, λ0]dP (L)
=
∫
L
∫
Y,D
(Dκ− Y )p(Y,T |A= a,L, δ = 0, ω1:n, θ1:n, λ0)dP (L)
Note above, Y and D are the spaces we integrate over. This last line is each term of Equation
(3). The second line follows from joint ignorability (IA.1), allowing us to condition on A=
a, δ = 0 after first conditioning on L. The third line follows from joint consistency, IA.2,
allowing us to drop the superscripts on monetary value. These are extensions of the usual
conditional ignorability and consistency assumptions under censoring (Robins, Hernán and
Brumback, 2000) extended to handle a bivariate cost-survival time outcome. The interference
assumption, IA.4, allows us to write MV a1:n,01:n =MV a,0. That is, each subject’s potential
monetary value is independent of others’ treatments or censoring status. Said another we, we
learn nothing about someone else’s potential monetary value by learning another’s treatment
assignment. Joint positivity, IA.3, is requires so that we do not condition on a zero-probability
event in the second equality. The expression above identifies a causal estimand that is purely
a function of unknown parameters. Thus a posterior distribution over the parameters induces
a posterior distribution over monetary value.
APPENDIX B: POSTERIOR COMPUTATION
Gamma Process Prior Specification. This appendix provides additional details for up-
dating the baseline hazard model with a dependent Gamma process prior (Nieto-Barajas and
Walker, 2002). Much of this is a detailed overview of the results established by Nieto-Barajas
and others in their 2002 paper and outlined in documentation of the BGPhazard R package.
We provide an abbreviated presentation adapted to the context of our joint model for the
reader’s convenience.
Consider observing right-censored survival time data for i = 1, . . . , n subjects with sur-
vival time Ti and death indicator δi. Consider a partition, {τv}v=1:V , of the time interval such
that 0< τ1 < τ2 < · · ·< τV where τV >maxi(Ti). In a setting with fixed study end, τ , we
could set τV = τ . In this case we consider equally-spaced interval such that ∆v = τv − τv−1
for all v. A piecewise constant hazard model can be defined as
λ0(t) =
V∑
v=1
λ0vI(τv−1 < t≤ τv)
If a priori the baseline hazard λ0(t)∼GP (bλ∗0, b, ξ = 0), then the hazard rate in each interval
follows λ0v ∼Gam(bλ∗0v, b), where the first argument in the shape and the second argument
is the rate. In the shape, we’ve defined λ∗0v = {Λ∗0(τv)− Λ∗0(τv−1)}/∆v , where Λ∗0 denotes
the prior cumulative hazard. Thus the prior mean hazard at each interval is E[λ0v] = λ∗0v .
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This is known as the independent Gamma process prior because the hazard at each increment
is independent a priori. The dependent Gamma process of Nieto-Barajas extends this pro-
cess to introduce dependence between hazards in nearby increments - providing a smoother
estimate that is less dependent on choice of time partition. They do this by introducing
latent processes {cv}1:V and {uv}1:V and is denoted with GP, as above, but with ξ > 0.
The process is initialized with λ1 ∼ Gam(bλ∗01, b). Now for v ∈ {1,2, . . . τ − 1}, we have
uv | λv, cv ∼ Pois(cvλ0v) and λ0v+1 | uv, cv ∼Gam(bλ∗0v+1 + uv, b+ cv). The conditional
prior mean of this process is
E[λ0v | λ0v−1] =
bλ∗0v + cv−1λ∗0v−1
b+ cv−1
So the prior mean baseline hazard rate in current interval v is a weighted average of the prior
baseline hazard rate, λ∗0v , in the current time interval and the prior baseline hazard rate in
the previous time interval, λ∗0v−1. This is the induced AR(1) smoothness of the dependent
Gamma Process. Following, Nieto-Barajas we place a hyperprior on {cv}1:V , assuming cv |
ξ
iid∼ Exp(ξ). Where the prior mean is E[cv] = ξ. The magnitude of ξ (relative to b) controls
the aggressiveness of the prior AR(1) shrinkage. if ξ >> b, then on average cv−1 >> b at all
intervals v, meaning thatE[λ0v | λ0v−1]≈ λ∗0v−1. Similarly, if ξ << b, thenE[λ0v | λ0v−1]≈
λ0v - i.e. almost no shrinkage to the previous hazard. It can be shown above that setting ξ = 0
above reduces this to the independent Gamma process.
Thus, the notation λ0 ∼GP (bλ∗0, b, ξ) denotes this prior for the piecewise constant model
λ0(t). Specifically, the joint prior is
(7)
p(λ01:V , c1:V , u1:V | b, ξ) = p(λ1)p(u1 | λ01, c1)
V∏
v=2
p(uv | λv, cv)p(λ0v | uv−1, cv−1)
V∏
v=1
p(cv | ξ)
With hyperparameters b, ξ, and λ∗0. Notational dependence on λ∗0 has been suppressed for
compactness. This can be combined with the likelihood for the observed data to obtain con-
ditional posteriors for each of the three parameter blocks, λ01:V , c1:V , and u1:V . We discuss
likelihood construction in the next section. b
Gamma Process Likelihood Construction. Now we consider the GP (bλ∗0, b, ξ) prior
for the baseline hazard in a proportional hazard model λ(t | Xi, θi) = λ0(t) exp
(
X ′iθi
)
,
where λ0(t) =
∑V
v=1 λ0vI(τv−1 < t ≤ τv) . Specifically, our goal is to find the posterior
p({λ0v}1:V ,{cv}1:V ,{uv}1:V | D), where D indicates the observed data.
For convenience in presentation, define ηi = X ′iθi. Also note that under the piece-wise
constant model, the cumulative hazard is Λi(t) =
∫ t
0 λ0(s)e
ηids=
∑V
v=1 λ0ve
ηi∆v(t). Here,
∆v(t) = (t− τv−1)I(t ∈ (τv−1, τv]) + ∆vI(t > τv).
Conditional on θi, standard survival likelihood construction with right-censored data
yields
p(Ti |Xi, θi, δi, λ01:V ) =
∏
i|δi=1
f(Ti |Xi, θi)
∏
i|δi=1
S(Ti |Xi, θi)
Subjects with an event contribute to the likelihood via the density, f , and censored subjects
contributed via the survival function S, both of which can be expressed in terms of the hazard.
Denote λ0vi as the hazard rate of the increment in which subject i died. The density evaluated
at subject i’s death time is,
(8) f(Ti |Xi, ηi) = λ0(Ti)e−Λi(Ti) = λvieηi exp
{
−
V∑
v=1
λ0ve
ηi∆v(Ti)
}
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The survival function in terms fo the hazard is,
S(Ti |Xi, θi) = exp
{
−Λi(Ti)
}
= exp
{
−
V∑
v=1
λ0ve
ηi∆v(Ti)
}
So the full likelihood is
p(Ti |Xi, θi, δi, λ01:V ) =
( ∏
i|δi=1
λ0vi
)
exp
{ ∑
i|δi=1
ηi
}
exp
{
−
V∑
v=1
λ0v
( n∑
i=1
eηi∆v(Ti)
)}(9)
Gamma Process Posterior Updates. The likelihood (9) can be combined with the joint
prior (7) to obtain the following conditional posteriors distributions for u1:V , c1:V , and λ01:V .
Note all of these distributions are also conditional on data, D. First, the conditional posterior
distribution of {cv}1:V is
(10)
p(cv | uv, λov+1, λ0v)∝
{
cuvv exp
{
− (λ0v + λ0v+1 + 1ξ )cv
}
(b+ cv)
λ∗0v+1+uv v = 1, . . . , V − 1
Gam(uv + 1, λ0v +
1
ξ ) v = V
For v = 1, . . . , V − 1 this update is not conjugate. We sample each cv separately using Adap-
tive Metropolis-Hastings with separate proposal variances for each cv . The proposal vari-
ances are tuned every few iterations in the burn-in period to target a 23.4% acceptance rate,
which has been shown to be optimal in around 10-dimensional sampling problems (Roberts
and Rosenthal, 2001). The latent process {uv}1:V can be updated from the following condi-
tional posterior,
(11) p(uv | cv, λ0v+1, λ0v)∝

[
cvλ0vλ0v+1(b+cv)
]uv
Γ(uv+1)Γ(λ∗0v+1+uv)
v = 1, . . . , V − 1
Pois(cvλ0v) v = V
Note here uv is integer-valued and non-conjugate for v = 1, . . . , V − 1. To sample from
these conditional posteriors, we use grid sampling with a large grid of points {0, . . . ,10000}.
Finally, the conditional posteriors of the hazard rate in each interval is given by
(12)
p(λ0v | −,D) =
{
Gam
(
d1 + u1 + λ
∗
01, c1 + b+
∑n
i=1 e
ηi∆1(Ti)
)
v = 1
Gam
(
dv + uv + uv−1 + λ∗0v, b+ cv + cv−1 +
∑n
i=1 e
ηi∆v(Ti)
)
v = 2, . . . , V
Above, dv is the number of deaths in interval v. Note that the conditional distribution is fully
conjugate for all v and can be sampled directly. Note also that this update is the only Gamma
Process update that involves data. The processes u1:V and c1:V are latent and the updates do
not involve data - but they do induce a dependence between the λ0v, which now must be
updated sequentially and in order.
Concentration Parameters. The two concentration parameters of the EDP, αθ and αω ,
are given Gam(1,1) priors. We follow the implementation in Roy et al. (2018). Details can
be found in the supplement to their 2018 paper.
Monte Carlo Integration for Monetary Value. The expectation can be expressed as
µ(a,0) = κE[D | −]−
∫ τ
0
∫ ∞
0
E[Y |D,−]p(D | −)dY dD
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Note we use “−" to denote the conditioning set, which was made explicit in the main body
of the paper.
• The first term, E[D | −], (average death time within 2-years under treatment a) can be
computed in closed form. Since we partition time interval (see Appendix B) into K inter-
vals, the probability of dying in interval k is p(t ∈ [τk, τk + 1] | −). Within each interval,
death time is uniform - so mean is τk+1+τk2 .
E[D | −]≈
K∑
k=1
τk+1 + τk
2
· p(t ∈ [τk, τk + 1] | −)
At every iteration, p(t ∈ [τk, τk + 1] | −) is given by substituting the parameter draws in
this iteration into Equation (8).
• Second term: For each subject, draw death interval proportional to p(t ∈ [τk, τk + 1] | −).
Then, within each interval draw a death time t∗ uniformly within that interval. Compute
E[Y | T = t∗,−] using this drawn value and the parameter draws in the current iteration.
APPENDIX C: SIMULATION DETAILS
Data Generation. In the log-normal setting, we simulate data as follows. For subject
i= 1, . . . ,N ,
• Simulate latent cluster membership: ci ∼ Ber(pc), a 5-dimensional confounder Li. This
vector contains one continuous confounder drawn from a standard Normal distribution in
the first entry and four binary confounders draw from Bernoulli distribution with probabil-
ity .5.
• Simulate treatment:
Ai ∼Ber(expit(0 + (.1, .5,−.5, .5,−5)′Li))
• Simulate survival time, Ti: from a Weibull distribution (using the proportional hazard pa-
rameterization) with shape 10 and scale exp(ηi). Where
ηi = ci · [(0, .1,−.1, .1,−.1)′Li] + (1− ci) · [(1,−.1, .1,−.1, .1)]) + (−3 + 2ci)Ai
Notice that the treatment effect on survival is bimodal, along with the covariate effects.
• Simulate a covariate-dependent censoring time: Ci, from the same Weibull as above.
• Simulate Observed time observed time: Draw Zi ∼ Unif(0,1) and simulate censoring
indicator δ¯i = I(Ci <Di) · I(Zi < pδ). If δ¯i = 1, then Ti =min(Ci,Di).
• Simulate accumulated cost up to Ti:
Yi ∼ logN
(
mean= µi, sd= .05
)
where
µi = 2ci + (.1, .2, .2, .2, .2)
′Li − 2Ti + .3Ai
Here we have a bimodal cost distribution (different means depending on ci) but homoge-
neous treatment effect on costs.
• Output observed data Di = (Yi, Ti, δi = 1− δ¯i,Li,Ai).
In the Normal setting, we simulate data as above with the following modifications:
• Simulate survival and censoring times time with log scale parameter
ηi = ci · [(−1, .1,−.1, .1,−.1)′Li] + (1− ci) · [(1,−.1, .1,−.1, .1)]) + 2ci ·Ai
Note again that treatment and covaraite effects are bimodal (dependent on ci).
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• Simulate outcome data from a Normal distribution with standard deviation .5 and mean
µi = 5 + 5ci + (.1, .5, .5, .5, .5)
′Li − 3Ai + Ti
• Here the treatment and covariate effects on Y are homogeneous.
We simulate each dataset withN = 1500. In the bimodal setting, pc = .5. In the parametric
setting, the pc = 0 - so all subjects are from the same cluster. We set pδ = .4 in the high setting
to target 20% censoring and pδ = .1 in the low setting to target 5% censoring. For each setting
Normal/log-Normal -pδ-pc combination, we simulate 200 such datasets.
EDP-GP Prior Settings. First we discuss the settings for the log-Normal data generat-
ing mechanism. For the Gamma Process prior, we partition the interval from [0,max(Ti)]
into equal size increments of .1. We set ξ = 1e − 6 to be quite small (very flat) to allow
the likelihood to drive the posterior estimate. We set b= ξ thus inducing an AR1 dependence
between increments that is as informative as the shrinkage towards λ∗0, which we set to an ex-
ponential hazard with rate 400 - close to the average empirical hazard rate across time points.
Notice the actual baseline hazard is generated from a Weibull, so our prior is deliberately
misspecified as it likely would be in practice.
The prior on θi, G0θ is set to a multivariate Gaussian with zero mean vector and diagonal
covariance 32I6. Where I6 is the 6× 6 identity matrix, where 6 is the number of covariates
(5 confounders and one treatment indicator). This is flat on the hazard ratio scale.
Since we fit a Gaussian conditional model for Y , the prior G0ω is a product of a prior
on the covariate effects and prior on the variance. Regarding the former, we again use a
multivariate Gaussian with zero mean vector and covariance 32I7, where the identity matrix
has a diagonal entry for the five confounders, treatment indicator, and observed time. This is
fairly flat relative to the true conditional outcome variance (on log scale) of .052. The prior
for the variance is set to an inverse gamma distribution. In the bi-modal setting we set this
distribution to have shape and scale equal to 20. This centers the prior variance around 1. In
the parametric/unimodal setting we use a slightly tighter prior around 1 - with shape and rate
equal to 100. These tighter settings like 20 and 100 help regularize the Gaussian model we
fit to the skewed Y data.
For the Normal data generating mechanism much of the settings above is the same. We
only change the shape parameter of the inverse gamma distribution on the conditional cost
variance to be 5 with a rate of 20. This is a fairly flat prior.
For each data set, we run the MCMC sampler for 7000 iterations and discard the first 2000
as burn-in. This yields 5,000 posterior draws which we use for inference about NMB. In all
settings, we initialize the model with three ω clusters, each having three θ sub-clusters. This
initialization is very different from the true data generating mechanism that either generates
data from a single ω− θ cluster and two ω (top-level) clusters.
Since we fit a Gaussian model, each cluster’s conditional ω posterior is conjugate with our
Normal-Inverse-Gamma prior. This is a simple update. For the θ cluster parameters we use
a Metropolis update with Gaussian jumping distribution. The jumping covariance is identity
with .1 along the diagonals. Similarly, we use a Metropolis step to update {c1:v}1:V (see
Appendix B) at each step. Each cv is updated from an independent Gaussian jumping dis-
tribution with variance .5. We adapt both of these jumping distribution variances every 25
iterations starting from iteration 50 and ending at iteration 200 to target an acceptance rate of
23.4% per Roberts and Rosenthal (2001).
Doubly-Robust Implementation. Here we describe the doubly-robust NMB estimator
of Li et al. (2018) implemented in our simulations. The cost and survival time models are
estimated using super learner with regression trees, generalized additive models, generalized
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linear models, and GLM-Net included in the ensemble. We use a correctly specified logistic
regression for the treatment model. This is quite generous since doubly-robust estimators are
guaranteed to be consistent with a correctly specified treatment model (though the conver-
gence rate can be quite slow if the outcome model is very misspecified.).
Since we have covariate dependent censoring, we estimate the inverse censoring weights
using a discrete-time failure model as described in Section 3.1.1 of their paper. To summarize,
these weights are computed using estimates of the probability of censoring at each time point,
conditional on not having been censored before that time point. This is estimated using a
logistic regression of a censoring indicator at each time point on simulated confounders,
treatment and time-level fixed effects. Intervals are computed using a 95% BCa interval after
1502 bootstrap iterations (BCa intervals require more bootstrap iterations than observations
in the sample).
APPENDIX D: DATA ANALYSIS DETAILS
We partition the interval from [0,24] into increments of .5. To sample from conditional
posterior of {cv}1:V (as mentioned Appendix B) we use a Metropolis-Hastings update from
jumping variance of .5. To sample from the posterior of θ (the covariate effects of the hazard
model) we use a joint Metropolis-Hastings update with an initial identity covariance matrix
multiplied by .1 along the diagonal. For both samplers, we adapt these jumping variances
every 25 iterations starting from iteration 50 to iteration 200. Every 25th iteration we use the
previous 25 draws to target an acceptance rate of 23.4%, as per Roberts and Rosenthal (2001).
Since we assume a log-normal cost distribution, posterior updates are conjugate using log-
transformed cost. Figure 4 contains some diagnostic plots with a discussion in the caption.
These plots show the MCMC chains to be well-mixed and model fit to be adequate. The total
run-time was approximately 50 hours when parallelizing the three chains.
For the doubly-robust (DR-SL) implementation of Li et al. (2018), we estimate the propen-
sity score model, cost model, and survival model using super learner with regression trees,
GLM, and GLMnet as candidates. Inverse censoring probability weights were estimated us-
ing a discrete-time failure model described in Section 3.1.1 Li et al. (2018). This is a logistic
model that predicts the probability of censoring at each time point, conditional on not having
been censored before that time point. The discretization is at the monthly level, thus there are
24 intervals in which one can be censored over τ = 24 months. The resulting model is used
to predict the probability being censored at the observed time, for each subject. The inverse
of this probability is the weight used in the DR approach. We include all Age, Household in-
come, Charlson Index, and FIGO stage as covariates in each model. Due to small cell counts,
we combined FIGO stage II and II-NOS into a single category. In the discrete-time failure
model, we include a fixed effect for each month, 1-24. Due to sparsity, we included month
as a continuous covariate rather than categorical in this model. In Figure 5, displays NMB
estimates from this DR-SL model in gray, along with the EDP-GP estimates for reference.
Note the larger uncertainty in the DR-SL model.
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(a) (b)
(c) (d)
Fig 4: Diagnostic plots supporting data analysis results. Top row: traceplots of three MCMC
chains of posterior NMB draws (left) and distribution of the combined posterior NMB draws
of all chains (right). These NMB draws are based on κ= $50,000/12. All three chains mix
after starting with different initial clusters and seeds. Corresponding posterior is unimodal
and peaked around $14,500. Panel C shows the traceplots of three MCMC chains for DSI,
which mix well. Finally, panel D shows a kernel density estimate of the joint observed time
and cost distribution. In blue we show a single set of posterior predictive draws of joint cost
and observed time. This shows adequate model fit: the posterior predictive is placing mass
around the observed data. Moreover, the posterior predictive allows for occasional large cost
draws. This indicates the local log-Normal cost distribution is able to capture skewness. If,
for instance, the posterior predictive draws did not overlap with the observed data, we would
be suspicious of the model fit.
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Fig 5: NMB mean and 95% bootstrap intervals for various willingness to pay from the DR-SL
model in gray. The EDP-GP estimates from Figure 3a are shown in blue for reference.
